3P Biopharmaceuticals (3P), a Noáin, Spain-headquartered contract development and manufacturing organization for biologics, has signed a collaboration agreement with Ondek, a Sydney, Australia-based biopharmaceutical company developing natural immune modulatory products, for the production of an immunotherapy drug candidate based on the Helicobacter pylori organism.

The agreement will allow Ondek to transfer its proprietary technology to the production site of 3P Biopharmaceuticals, where 3P will perform the scale up and non-GMP manufacture of the drug candidate under anaerobic conditions of the H. pylori product that will be used for preclinical studies.

Ondek’s H. pylori-based technology platform uses the bacterium’s immune regulatory properties to develop products that will be orally administered for improved management of allergic indications and potentially other chronic inflammatory diseases.

Source: 3P Biopharmaceuticals